OVID vs. ATOS, GBIO, OMER, RENB, RIGL, GALT, MACK, TRVI, GTHX, and LFCR
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Atossa Therapeutics (ATOS), Generation Bio (GBIO), Omeros (OMER), Renovaro (RENB), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Merrimack Pharmaceuticals (MACK), Trevi Therapeutics (TRVI), G1 Therapeutics (GTHX), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
Atossa Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
Ovid Therapeutics received 114 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 70.49% of users gave Ovid Therapeutics an outperform vote while only 64.97% of users gave Atossa Therapeutics an outperform vote.
Atossa Therapeutics has a net margin of 0.00% compared to Atossa Therapeutics' net margin of -13,351.53%. Ovid Therapeutics' return on equity of -31.79% beat Atossa Therapeutics' return on equity.
In the previous week, Atossa Therapeutics had 11 more articles in the media than Ovid Therapeutics. MarketBeat recorded 21 mentions for Atossa Therapeutics and 10 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.67 beat Atossa Therapeutics' score of 0.12 indicating that Atossa Therapeutics is being referred to more favorably in the media.
Atossa Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 231.33%. Ovid Therapeutics has a consensus price target of $8.08, suggesting a potential upside of 139.86%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Therapeutics is more favorable than Ovid Therapeutics.
Atossa Therapeutics has higher earnings, but lower revenue than Ovid Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 7.8% of Atossa Therapeutics shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Atossa Therapeutics beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ovid Therapeutics Competitors List
Related Companies and Tools
